FGFR2b is an emerging protein biomarker overexpressed in ~ 38%* of advanced gastric/GEJ cancer patients2
The clinical impact of targeting FGFR2b in 1L gastric/GEJ cancers is being evaluated1,3
Amgen is committed to exploring the full potential of FGFR2b as an emerging biomarker
*FGFR2b protein overexpression is defined as any percentage of tumor cells with moderate (2+) to strong (3+) membranous staining, as detected by IHC.2
1L, first line; FGFR2b, fibroblast growth factor receptor 2, isoform IIIb; GEJ, gastroesophageal junction; IHC, immunohistochemistry.
References: 1. Wainberg ZA, et al. Gastric Cancer. 2024;27:558-570. 2. Rha SY, et al. JCO Precis Oncol. 2025;9:e2400710. 3. Sato Y, et al. J Clin Med. 2023;12:4646.
References: 1. FPO 2. FPO 3. FPO
